← All stories
Markets
FDA approves Takeda’s Mimrylo for polycythemia vera treatment
2 outlets - including Investing and Financialpost - are covering this story. MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV) MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in…
Covered by 2 outlets
All coverage · 3 articles
Investing.com Canada
·1h ago
FDA approves Takeda’s Mimrylo for polycythemia vera treatment
Financial Post
·1h ago
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV) MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in…
Investing.com News
·1h ago